infectious disease therapeutics Market

The infectious disease therapeutics market was valued at US$ 1,19,708.77 million in 2022 and is expected to reach US$ 1,67,883.93 million by 2030. The market is estimated to register a CAGR of 4.3% from 2022 to 2030.

Infectious diseases can transfer from one person to another through direct or indirect contact. Patients must take medications with anti-infective properties to treat infectious diseases. Pathogens such as bacteria, fungi, viruses, and parasites are the primary cause of these disorders. In order to target the organism causing the sickness and implement a remedy, the host's defensive system is directly targeted. A huge geriatric population has presented a significant opportunity for the market for infectious disease therapeutics to grow in the coming years.

Research and development (R&D) is a critical part of the business of biopharmaceuticals and pharmaceutical companies. R&D enables them to launch new products with significant medical and commercial potential for several therapeutic applications.

The following are a few of the major projects that the manufacturers have funded:

- In June 2022, GSK plc invested US$ 1.21 billion (?1 billion) over ten years to accelerate R&D dedicated to infectious diseases. New investment supports innovation in malaria, tuberculosis, and HIV, with additional emphasis on Neglected Tropical Diseases and antimicrobial resistance.

- In March 2022, the decision by the Canadian government to provide US$ 48.07 million (CAD 60 million) to the Global Fund's COVID-19 Response Mechanism (C19RM) was applauded by the Global Fund to Fight AIDS, Tuberculosis, and Malaria. The additional financing will assist in providing low- and middle-income nations with life-saving diagnostic procedures, medical oxygen, and personal protective equipment (PPE).

- In September 2021, the Biden-Harris Administration announced a US$ 2.1 billion investment to enhance infection prevention and control initiatives in the US public health and healthcare sectors. In order to address state, municipal, and territorial health agencies and other partner organizations that deal with infectious diseases in the US, the Biden-Harris administration has made financial investments in US rescue programs through the Centers for Disease Control and Prevention (CDC).

Thus, rising focus on R&D and funding in infectious disease therapeutics drive growth in the market.

By Product, Infectious Disease Therapeutics Market-Based Insights

Based on the drug type, the infectious disease therapeutics market, by drug class, is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022; the anti-bacterial segment is likely to register the highest CAGR in the infectious disease therapeutics market from 2022-2030. Anti-viral agents are drugs approved by the US Food and Drug Administration (FDA) for treating viral infections. Anti-viral agents typically target distinct phases of the viral life cycle. Anti-viral medications can be used for prevention, treatment, suppression, or overt disease.

By Indication, Infectious Disease Therapeutics Market-Based Insights

Based on the indication, the infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV segment held the largest market share in 2022 and is anticipated to register the highest CAGR from 2022 to 2030. HIV weakens an individual's immune system by destroying important cells that fight disease and infection. Due to various factors, including sexual partners and risky behaviors, some groups of people in the US are more likely to contract HIV than others. The risk of getting an infection after surgery can rise due to growing immune system suppression by HIV. The number of patients with HIV infection has been steadily rising in recent years. The life expectancy of HIV infection and AIDS patients has significantly increased since the introduction of antiretroviral therapy (ART).

Healthcare-Associated Infections, the National Institute of Health, and the Centers for Disease Control and Prevention are a few of the major primary and secondary sources referred to while preparing the report on the infectious disease therapeutics market.